Bli medlem
Bli medlem

Du är här


Saniona: Has obtained patent in the United States until 2033 for the combination of tesofensine and Metoprolol

Saniona, a leading biotech company in the field of ion channels, today
announces that the United States Patent and Trademark Office has
issued a patent covering the combination of tesofensine and
Metoprolol. The patent for Tesomet expires in the U.S. in 2033.

"This is an important patent for Saniona. Tesomet represents an
innovative new treatment opportunity for type 2 diabetes, which we
believe has a significant potential. We are planning to start Phase
2a studies during the first half of 2016," says Jørgen Drejer, CEO of

Saniona has previously informed about the notice of allowance for U.S.
patent application (US14/379,032) covering the combination of
Tesofensine and Metoprolol. It is this patent which has been issued
with the identification number US 9,211,271 B2.

The invention covered by the U.S. patent relates to the use of
pharmaceutical compositions comprising a therapeutically effective
combination of Tesofensine and Metoprolol for preventing the
cardiovascular side effects of Tesofensine, while leaving the robust
inhibitory efficacy on food intake and body weight loss unaffected.
The patent claims cover a method of treatment, prevention or
alleviation of obesity, a pharmaceutical composition of Tesofensine
and Metoprolol for use as a medicament and a kit comprising
Tesofensine and Metoprolol as well as the use hereof.

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail:

About Saniona

Saniona is a research and development company focused on drugs for
diseases of the central nervous system, autoimmune diseases,
metabolic diseases and treatment of pain. The company has a
significant portfolio of potential drug candidates at pre-clinical
and clinical stage. The research is focused on ion channels, which
makes up a unique protein class that enables and controls the passage
of charged ions across cell membranes. Saniona has ongoing
collaboration agreements with Upsher-Smith Laboratories, Inc.,
Productos Medix, S.A de S.V and Saniona's Boston based spinout
Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Idec
Inc. Saniona is based in Copenhagen, Denmark, where it has a research
center of high international standard. Saniona is listed at
AktieTorget since April 2014 and has about 3,000 shareholders. The
company's share is traded under the ticker SANION. Read more at

About Tesomet

Tesomet is a fix-dosed combination of tesofensine and metoprolol,
which Saniona plans to position for treatment of type 2 diabetes. In
addition to obesity, tesofensine has also the potential to reverse
the progression of type 2 diabetes by reducing liver fat. The market
for type 2 diabetes is estimated to grow from US $ 23 billion in 2014
to 43 billion USD 2023 due to the increasing problems with obesity.
Type 2 diabetes is considered as a progressive chronic disease today.
However, recent published research concludes that type 2 diabetes is
reversible and that large patient populations may undergo long-term
remission if they achieve a substantial weight loss through reduced
food consumption.

Saniona believes that tesofensine represents an interesting new
treatment option for type 2 diabetes, which not only may be used in
parallel with existing treatments, but also may offer potentially
long-term remission in many patients by contributing to a substantial
weight loss. In general, tesofensine has been well tolerated in human
clinical studies. However, an increase in heart rate has been
observed at therapeutic relevant doses of tesofensine. Patent
applications have been filed in respect of the combination
tesofensine and a beta blocker. Saniona has received notice of
allowance of a U.S. patent application, which includes a combination
of tesofensine and metoprolol and which can provide protection in the
United States until 2033, if issued. The combination product is
covered by other recent Saniona patent applications with broad
geographic coverage. Saniona has recently published new results from
datamining of previous clinical studies, which show that tesofensine
improved glycaemic parameters in prediabetes individuals
participating in a Phase 2 obesity study and that metoprolol blunts
the increase in heart rate caused by tesofensine in volunteers in a
Phase 1 study. Saniona expects to initiate a Phase 2a study during
the first half of 2016 for Tesomet in type 2 diabetes patients.


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.